| General Information of Drug Metabolite (DM) (ID: DM001988) |
| DM Name |
Erdafitinib metabolite M6
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 2D6 (CYP2D6)
|
DME0009
|
| Oxidation - O-Demethylation |
Erdafitinib
|
[1] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| Erdafitinib |
DR0595
|
Approved |
Renal cell carcinoma |
|
|
| References |
| 1 |
Metabolism and disposition in rats, dogs, and humans of erdafitinib, an orally administered potent pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor Xenobiotica. 2021 Feb;51(2):177-193. doi: 10.1080/00498254.2020.1821123.
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
